Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: March 22, 2023

Details for Patent: 8,067,427

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,067,427 protect, and when does it expire?

Patent 8,067,427 protects CAPRELSA and is included in one NDA.

This patent has forty patent family members in thirty-three countries.

Summary for Patent: 8,067,427
Title:Pharmaceutical compositions comprising ZD6474
Abstract: A pharmaceutical composition comprising ZD6474 or a pharmaceutically acceptable salt thereof, a brittle diluent and a second diluent which is practically insoluble and has ductile compression properties.
Inventor(s): Stott; Paul William (Wilmington, DE)
Assignee: AstraZeneca AB (Sodertajle, SE)
Application Number:11/596,979
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,067,427

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-002 Apr 6, 2011 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,067,427

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0411378.3May 21, 2004
PCT Information
PCT FiledMay 18, 2005PCT Application Number:PCT/GB2005/001931
PCT Publication Date:December 01, 2005PCT Publication Number: WO2005/112934

International Family Members for US Patent 8,067,427

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 049059 See Plans and Pricing
Argentina 110045 See Plans and Pricing
Austria 439841 See Plans and Pricing
Australia 2005244650 See Plans and Pricing
Brazil PI0511253 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.